Literature DB >> 9361180

The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis.

S Inuzuka1, T Ueno, T Torimura, S Tamaki, H Sugawara, R Sakata, N Kusaba, M Sata, K Tanikawa.   

Abstract

BACKGROUND: We examined the relationships among vitronectin (VN), plasminogen activator inhibitor-1 (PAI-1), and transforming growth factor beta 1 (TGF-beta 1) in liver diseases to evaluate the presence of plasmin cascade in human hepatic fibrosis.
METHODS: Blood and liver tissues were obtained from 57 patients with liver disease. Plasma VN, PAI-1 antigen, and PAI-1 activity levels were evaluated. Biopsied liver specimens were observed by light and electron microscopy after immunohistochemical staining. Morphometric analysis was performed on these specimens.
RESULTS: Plasma VN and PAI-1 activity levels decreased significantly with the progression of hepatic fibrosis and were particularly marked in the liver cirrhosis group. Plasma PAI-1 antigen level increased significantly. The immunolocalization of the active form of TGF-beta became more intense with the progression of hepatic fibrosis, whereas that of the dual-stained positive areas of PAI-1 and VN (PAI-1.VN) decreased. There was a positive correlation between TGF-beta and PAI-1, whereas there was a negative correlation between TGF-beta and PAI-1.VN. Immunoelectron microscopy showed the localization of PAI-1-VN in the extracellular space around the sinusoidal cells or surface of aggregating platelets, TGF-beta mainly in Ito cells, and VN in hepatocytes near the focal necrotic area or fibrous septa.
CONCLUSIONS: These findings suggest that VN and PAI-1 are related to the active form of TGF-beta and that it is possible that the plasmin cascade is present in the human liver.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9361180     DOI: 10.3109/00365529709011224

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver.

Authors:  J G Fan; L H Chen; Z J Xu; M D Zeng
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

2.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

3.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.

Authors:  Lawrence C Thompson; Sumit Goswami; David S Ginsberg; Duane E Day; Ingrid M Verhamme; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

4.  Cross-talk between human mast cells and bronchial epithelial cells in plasminogen activator inhibitor-1 production via transforming growth factor-β1.

Authors:  Seong H Cho; Sun H Lee; Atsushi Kato; Tetsuji Takabayashi; Marianna Kulka; Soon C Shin; Robert P Schleimer
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

5.  A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis.

Authors:  Kenneth H Minor; Christine R Schar; Grant E Blouse; Joseph D Shore; Daniel A Lawrence; Peter Schuck; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2005-05-19       Impact factor: 5.157

6.  The polysaccharides from Grifola frondosa attenuate CCl4-induced hepatic fibrosis in rats via the TGF-β/Smad signaling pathway.

Authors:  Chao Li; Meng Meng; Mingzhu Guo; Mengyang Wang; Aining Ju; Chunling Wang
Journal:  RSC Adv       Date:  2019-10-21       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.